Hematopoietic Stem Cell Transplantation | CHOP Research Institute
 

Hematopoietic Stem Cell Transplantation

This study involves taking the study drug, abatacept, by intravenous (IV) infusion.
Published on
Jan 5, 2022
Researchers evaluated whether the standard treatment for a rare disease called agammaglobulinemia is cost-effective in the United States.

The Olson Lab aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes.

Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.

E-mail:
levyerezd [at] chop.edu

Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.

E-mail:
olsont [at] chop.edu